NasdaqGM - Delayed Quote USD

Pharming Group N.V. (PHAR)

9.80 +0.20 (+2.09%)
At close: April 26 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Sijmen de Vries M.B.A., M.D. President, CEO & Executive Director 1.44M -- 1959
Mr. Jeroen Wakkerman Chief Financial Officer -- -- 1969
Ms. Mireille Sanders M.Sc. Chief Operations Officer -- -- 1968
Susanne Embleton Investor Relations Manager -- -- --
Mr. Ruud Van Outersterp Chief Ethics & Compliance Officer -- -- 1964
Dr. Anurag Relan M.D., MPH Chief Medical Officer -- -- 1972
Mr. Stephen Toor Chief Commercial Officer & GM Americas -- -- 1971
Dr. Alexander Breidenbach M.B.A. Chief Business Officer -- -- 1964
Dr. Bruno M. L. Giannetti Consultant -- -- 1952

Pharming Group N.V.

Darwinweg 24
Leiden, 2333 CR
Netherlands
31 71 524 7400 https://www.pharming.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
382

Description

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Corporate Governance

Pharming Group N.V.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 4; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

PHVS Pharvaris N.V.
23.35
+2.55%
 
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
 
VVY.AS Vivoryon Therapeutics N.V.
0.8000
-2.44%
 
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%
 
ALTHX.PA Theranexus Société Anonyme
1.1350
+1.34%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
HBP.TO Helix BioPharma Corp.
0.2100
0.00%
 
SEER Seer, Inc.
1.9100
+9.14%
 
BIOS.BR BioSenic S.A.
0.0156
-4.29%
 
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%